Shares of Leidos Holdings surged 6.1% to $125.95 after the defense contractor delivered a Q2 earnings beat that wasn't even close. Non-GAAP earnings of $3.26 per share crushed the consensus estimate of $2.90 by 12.4% , while revenue of $4.56 billion topped expectations of $4.36 billion by 4.5% . The results prompted management to raise full-year guidance across the board — but investors should look beneath the headline to understand where the growth is really coming from and what risks remain.

The Defense Business Is Winning New Work at a Remarkable Clip

Leidos's defense segment posted a 2.2 book-to-bill ratio in Q2 — meaning it booked $2.20 in new contracts for every $1 of revenue delivered — driven by major wins in munitions, unmanned surface vessels, and space payloads.

Notable awards included a $475 million F-16 support contract and a $456 million Military OneSource deal.

Management expects defense growth to accelerate to high single digits for the full year. For shareholders, a swelling backlog — now $48.7 billion, with funded backlog up 44% year-over-year — provides revenue visibility well into 2028 and beyond.

A Health Segment Setback Is Baked Into the Guidance — for Now

The VA suspended incentive payments for medical disability exams due to administrative reviews , and health segment revenues contracted in Q2 after a fourth vendor was added to a key contract.

Management expects health revenue to stay near Q2 levels for the rest of 2026, with roughly 20% operating margins. The question is whether this stabilization holds or deteriorates further.

Cash Generation Hit a Quarterly Record

Leidos generated $793 million in operating cash flow and $761 million in free cash flow.

It used $300 million to pay down debt and returned $127 million to shareholders through buybacks and dividends. That firepower matters: long-term debt climbed to $6.01 billion from $4.63 billion , largely due to the Entrust acquisition, so deleveraging speed is now a key metric to watch.

Raised Guidance Signals Confidence, but the Bar Is Higher

Leidos raised its 2026 revenue guidance midpoint by $100 million, EPS guidance by $0.05, and operating cash flow guidance by $50 million. Still, at $125.95, the stock trades roughly 16% below the pre-earnings analyst target of ~$150.67. That gap suggests Wall Street sees further upside — if defense momentum holds and health headwinds prove temporary rather than structural.